NBIX insider exercised options and sold 106,322 shares under 10b5-1 plan
Rhea-AI Filing Summary
Dr. Kevin Charles Gorman, a director of Neurocrine Biosciences (NBIX), exercised 106,322 non-qualified stock options with an exercise price of $35.99 and sold 106,322 resulting shares on 08/07/2025. The sales were effected by a broker under a Rule 10b5-1 trading plan adopted on February 24, 2025, at a weighted-average price of $126.4111 per share (sales ranged $124.80–$129.03). After the transactions, Dr. Gorman beneficially owns 514,596 shares; 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which he has voting and investment power. The options were granted on February 5, 2016, vested in monthly installments, and were due to expire on February 5, 2026. The disposition was effected pursuant to the pre-arranged 10b5-1 plan and the issuer’s policy prevents amendment of that plan after adoption.
Positive
- Sale was executed under a Rule 10b5-1 trading plan, indicating the transactions were pre-arranged rather than opportunistic.
- Filing discloses the weighted-average sale price and the range of execution prices, providing transparent pricing information.
Negative
- Reporting person disposed of 106,322 shares, reducing beneficial ownership from 620,918 to 514,596.
- A substantial portion of the exercised option shares were sold immediately, which may be viewed negatively by some investors monitoring insider selling.
Insights
TL;DR: Director exercised options and immediately sold the shares under a pre-set 10b5-1 plan at a high weighted-average price.
The Form 4 shows an exercise of 106,322 options at $35.99 and subsequent sale of the same number of shares on 08/07/2025 under a Rule 10b5-1 trading plan adopted 02/24/2025. Sales executed at a weighted-average price of $126.4111 (range $124.80–$129.03), reducing the reporting person’s beneficial ownership from 620,918 to 514,596. This is a routine exercise-and-sell under a pre-arranged plan, so the transaction alone is unlikely to change the company’s fundamentals.
TL;DR: Use of a 10b5-1 plan and a non-amendable issuer policy points to a pre-planned, governance-compliant insider sale.
The filing explicitly states the sale was executed by a broker pursuant to a Rule 10b5-1 plan adopted 02/24/2025 and that issuer policy restricts amending that plan after adoption. The disclosure also details the option grant date (02/05/2016) and expiration (02/05/2026), which supports transparency about the origin of the sold shares. From a governance perspective, the clear disclosure of the plan and price range is a positive compliance signal for investors monitoring insider selling practices.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option | 106,322 | $0.00 | -- |
| Exercise | Common Stock | 106,322 | $35.99 | $3.83M |
| Sale | Common Stock | 106,322 | $126.4111 | $13.44M |
Footnotes (1)
- The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $124.80 to $129.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026.
